Physician profile
Robert W Phares
NPI 1083666598
$379.30
in general payments reported to CMS, 2019-2025
17 companies · $52.79 in 2025
The $52.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $20.36 · 2022: $17.29 · 2023: $30.06 · 2024: $83.70 · 2025: $52.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.40 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $44.47 | 2019-2024 | |
| Pfizer INC. | $34.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.35 | 2023-2024 | |
| Lilly USA, LLC | $29.87 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.36 | 2020 | |
| Vanda Pharmaceuticals INC. | $19.09 | 2024 | Hetlioz, Fanapt |
| Boston Scientific Corporation | $17.51 | 2025 | Watchman Flx |
| Genentech USA, INC. | $17.31 | 2019 | |
| Alkermes, INC. | $17.29 | 2022 | |
| Indivior INC. | $15.92 | 2023 | Sublocade |
| Tandem Diabetes Care, INC. | $15.59 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.51 | 2025 | Xifaxan |
| Dexcom, INC. | $14.31 | 2024 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.39 | 2019 | |
| Medtronic Minimed, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Phares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.